Type of Mobilization Agent Impacts CD34+ Cell Collection Yields for Patients with Sickle Cell Disease Undergoing Gene Therapy: A Single-Center Analysis

Key Points

• CD34+ cell collection yields are significantly affected by the type of mobilization agent used.
• Key evidence indicates varying efficiencies realized through different agents in 30 sickle cell disease subjects.
• Observational analysis at a single center explored mobilization agents and their effects on cell yields for therapy.
• These findings may enable more effective gene therapy protocols, yet broader studies are necessary for validation.